Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Symptoms of RA for no more than 12 months prior to enrollment
Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 criteria for classification of RA
Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX \< 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses
At least 3 tender \& 3 swollen joints
Anti-cyclic citrullinated peptide (CCP) \> 3X the upper limit of normal and positive rheumatoid factor
You may not be if
History of other autoimmune diseases (eg, psoriasis, systemic lupus, erythematosus, etc)
Prior use of non-biologic therapy other than methotrexate
Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) therapy
Subjects with chronic or recent acute serious infection
Clareo Health | Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
